

Performance of top companies in Jun'26

Company	MAT growth (%)	Jun'26 (%)
IPM	11.1	16.0
Abbott*	8.9	16.4
Ajanta	15.1	18.3
Alembic	2.1	13.1
Alkem*	10.0	16.4
Cipla*	10.6	18.7
Dr Reddys	13.5	17.7
Emcure*	4.6	6.8
Eris	9.6	13.8
Glaxo	8.5	14.2
Glenmark	14.6	19.2
Intas	15.8	20.8
Ipca	11.7	14.6
Lupin	13.0	17.5
Macleods	11.5	15.9
Mankind	9.0	15.1
Sanofi	11.5	11.0
Sun*	12.7	17.0
Torrent	11.9	19.9
Zydus*	11.7	19.8

Acute/Chronic witness highest YoY growth in 24m

- IPM grew 16% YoY in Jun'26, compared to 12% in Jun'25 and 12% in May'26. On a 12-month (MAT) basis, IPM growth stood at 11.1% YoY.
- Growth was driven by strong outperformance in Cardiac, Anti-diabetic and VMN therapies, which exceeded overall IPM growth by ~ 450bp, 430bp and 300bp, respectively, in Jun'26.
- Acute therapies continued to witness 13% YoY growth in Jun'26, compared to 10% in May'26 and 11% in Jun'25.
- The chronic therapy segment maintained robust double-digit growth of 20% YoY, supported by an increased focus on chronic portfolios amid evolving lifestyle trends in the domestic market.
- For the 12 months ending in Jun'26, IPM growth was driven by 3.4%/4.6%/3.1% YoY growth in volumes/prices/new launches.
- Mounjaro remained the top-selling drug in Jun'26 with sales of INR1.4b, followed by Foracort at INR0.8b, according to IQVIA.
- Mixtard continued to decline, reporting a 31% YoY drop in Jun'26, as per IQVIA data.

Intas/Torrent/Zydus outperform in Jun'26

- Among the top 20 pharma companies, Intas (+20.8%YoY), Torrent (+19.9%YoY) and Zydus (+19.8%) outperformed the overall IPM in Jun'26.
- Emcure (+6.8%YoY), Sanofi (+11%YoY) and Alembic (+13.1%YoY) were the key underperformers during the month.
- Torrent outperformed IPM, driven by superior growth across Cardiac/ VMN.
- Zydus outperformed IPM, driven by momentum in Cardiac/Respiratory/ Antineoplast.
- Corono Remedies reported industry-leading price growth of 8.2% YoY on MAT basis. Intas reported the highest volume growth of 9.6% YoY on MAT basis. Ajanta Pharma posted the highest growth in new launches of 5.4% YoY on MAT basis.

Cardiac/Anti-Diabetic/Respiratory lead YoY growth on MAT basis

- On MAT basis, the industry reported 11.1% growth YoY.
- On MAT basis, chronic therapies posted 15.2% YoY growth, while acute therapies recorded 8.5% YoY growth in Jun'26.
- The acute segment's share in overall IPM stood at 59.3% for MAT Jun'26.
- Cardiac/Anti-Diabetic/VMN grew by 20.5%/20.3%/19.0%YoY. AI/Gastro/Derma underperformed IPM by ~590bp/350bp/300bp on YoY basis for 12 months ending in Jun'26.

MNCs continue to outperform domestic companies in YoY growth

- As of Jun'26, Indian pharma companies retained a dominant 84% market share in IPM, with the remainder held by MNCs.
- In terms of growth, Indian companies expanded by 16% YoY, while MNCs outpaced them with 19% YoY growth in Jun'26.


Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com) **Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com)

Khyati Sonthalia - Research Analyst (khyati.sonthalia@motilalOswal.com) | **Vipul Mehta - Research Analyst** (vipul.mehta@motilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.


Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Exhibit 1: IPM posted 16% YoY growth in Jun'26




Source: MOFSL, IQVIA

Exhibit 2: Acute/chronic therapies registered YoY growth of 13%/20%



Source: MOFSL, IQVIA

Exhibit 3: Indian companies/MNCs reported 16%/19% YoY growth



Source: MOFSL, IQVIA

Indian Pharma Market - Jun'26

Exhibit 4: Performance of top companies in Jun'26

Company	MAT Jun'26 value (INR b)	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month
				Sep'24	Dec'24	Mar'25	Jun'25	Sep'25	Dec'25	Mar'26	Jun'26	Jun'26
IPM	2,649	100	11.1	8.3	7.7	7.5	8.8	7.3	11.9	11.7	13.5	16.0
Sun Pharma	214	8.1	12.7	10.4	10.6	11.0	11.3	7.8	14.7	13.6	14.7	17.0
Abbott	167	6.3	8.9	9.7	10.0	8.4	8.5	6.7	6.9	9.5	12.4	16.4
Cipla	149	5.6	10.6	5.9	6.1	8.7	6.5	7.2	10.7	9.3	15.4	18.7
Mankind	125	4.7	9.0	8.4	5.0	6.1	9.0	6.2	8.6	8.6	12.7	15.1
Alkem	103	3.9	10.0	5.9	5.9	6.0	8.8	6.2	9.3	11.0	13.6	16.4
Lupin	92	3.5	13.0	8.6	6.4	6.2	7.4	5.6	14.2	15.0	17.4	17.5
Intas Pharma	101	3.8	15.8	13.6	9.9	9.7	11.1	9.7	17.6	17.9	18.0	20.8
Torrent	123	4.7	11.9	10.8	9.0	8.6	10.7	7.5	11.7	12.2	15.8	19.9
Macleods Pharma	87	3.3	11.5	3.3	3.7	3.9	7.7	12.6	11.1	9.8	12.3	15.9
Dr. Reddys	85	3.2	13.5	9.2	10.5	5.5	11.3	10.8	13.0	15.6	14.6	17.7
Zydus	76	2.9	11.7	10.8	8.1	9.8	8.7	6.8	13.8	11.3	14.9	19.8
GSK	57	2.2	8.5	0.7	1.3	0.2	3.8	3.0	11.0	9.6	10.8	14.2
Glenmark	59	2.2	14.6	12.3	9.4	10.2	14.7	11.4	16.1	12.5	18.3	19.2
Ipca	55	2.1	11.7	13.4	11.4	13.6	8.6	8.3	12.8	13.6	12.4	14.6
Emcure	58	2.2	4.6	7.3	4.5	5.1	7.3	3.1	6.5	3.7	5.0	6.8
Alembic	33	1.2	2.1	1.3	-1.6	-2.1	2.1	0.1	2.0	0.3	6.1	13.1
Eris Lifesciences	35	1.3	9.6	5.2	3.9	2.6	4.2	6.5	11.1	8.7	12.2	13.8
Ajanta	22	0.8	15.1	12.3	10.8	7.7	10.6	12.0	14.9	15.2	17.8	18.3


Source: IQVIA, MOFSL

Exhibit 5: Cardiac/Anti-Diabetic/VMN drive growth in Jun'26

Therapy	MAT Jun'26 value (INR b)	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month
				Sep'24	Dec'24	Mar'25	Jun'25	Sep'25	Dec'25	Mar'26	Jun'26	Jun'26
IPM	2,649	100.0	11.1	8.3	7.7	7.5	8.8	7.3	11.9	11.7	13.5	16.0
Cardiac	358	13.5	15.4	12.2	12.3	10.4	12.6	11.5	13.0	15.9	16.9	20.5
Gastro Intestinal	275	10.4	7.6	9.8	7.5	10.0	6.9	1.7	3.5	8.9	11.1	11.6
Anti-Infectives	270	10.2	5.2	8.2	2.5	3.9	6.7	4.5	4.9	4.0	8.5	10.6
Anti-Diabetic	242	9.1	14.5	9.1	9.0	7.0	8.6	9.4	11.8	15.3	17.3	20.3
Respiratory	211	7.9	11.6	2.8	4.5	3.9	12.3	14.1	16.7	8.8	11.3	13.9
Vitamins/Minerals/Nutrients	209	7.9	12.1	8.1	8.0	7.7	8.1	6.4	7.8	13.8	16.3	19.0
Pain / Analgesics	207	7.8	9.5	7.7	7.8	6.6	7.0	5.0	6.0	11.5	13.2	15.9
Derma	179	6.8	8.1	9.8	11.1	7.5	6.1	2.7	4.3	9.2	11.3	12.3
Neuro / Cns	161	6.1	11.3	9.4	8.1	8.9	10.2	7.3	9.1	12.1	12.9	15.9
Gynaec.	127	4.8	10.5	3.1	3.5	3.6	5.6	6.3	7.2	11.5	12.1	15.5
Antineoplast/Immunomodulator	82	3.1	28.1	12.1	12.5	11.3	14.1	24.5	24.5	32.2	27.1	30.3
Urology	60	2.3	11.8	13.2	14.3	13.6	10.7	9.1	10.8	10.4	13.0	14.1
Ophthal / Otologicals	51	1.9	9.9	-4.0	10.5	8.0	8.7	5.6	7.1	11.5	11.1	15.0
Vaccines	41	1.6	17.4	8.8	7.4	10.0	10.4	12.7	14.4	17.8	18.5	24.0

Note: VMN: Vitamin/Minerals/Nutrients; Source: IQVIA, MOFSL

Exhibit 6: Acute as a percentage of total sales and growth rate on MAT basis in Jun'26



Source: MOFSL, IQVIA



Sun Pharma

Secondary sales grew 17% YoY in Jun'26 vs. 14.1% in May'26. Exceptional growth in Rosuvvas; strong growth in all other major brands, except Susten/Volini.

Strong growth in Anti-Diabetic/Pain/Cardiac was partially offset by subdued performance in Anti-Infectives.

Price and volume growth drove majority of the growth for MAT Jun'26 basis.


Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		2,14,130	12.7	100.0	14.7	17.0
Rosuvvas	Cardiac	6,413	20.0	33.7	29.4	36.0
Levipil	Neuro / Cns	4,916	12.8	37.3	17.3	20.2
Gemer	Anti Diabetic	3,854	10.9	10.3	16.3	19.5
Pantocid	Gastro Intestinal	3,784	20.7	20.7	19.5	22.2
Susten	Gynaec.	3,729	13.7	34.6	12.1	8.4
Pantocid-D	Gastro Intestinal	3,419	13.2	17.9	17.4	19.0
Sompraz-D	Gastro Intestinal	3,247	16.6	28.9	15.5	17.9
Montek-Lc	Respiratory	3,107	16.4	20.4	12.3	18.6
Volini	Pain / Analgesics	3,099	-6.2	29.2	-6.3	-1.8
Istamet	Anti Diabetic	2,636	26.3	25.2	32.6	34.4

Exhibit 7: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	12.7	14.7	17.0
Neuro / Cns	17.5	13.7	14.7	17.1
Cardiac	17.3	15.9	18.2	20.9
Gastro Intestinal	13.4	14.1	16.4	18.9
Anti Diabetic	8.4	19.6	25.3	27.1
Pain / Analgesics	7.9	11.9	17.4	23.6
Anti-Infectives	7.4	2.3	3.6	4.0


Source: IQVIA, MOFSL

Exhibit 8: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 9: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL

Cipla

Cipla

Exhibit 10: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		1,49,106	10.6	100.0	15.4	18.7
Foracort	Respiratory	10,688	15.7	61.3	16.1	10.9
Duolin	Respiratory	6,598	12.2	84.4	12.2	16.0
Budecort	Respiratory	5,784	18.7	80.5	27.1	27.9
Dytor	Cardiac	4,531	27.0	88.5	32.1	43.4
Montair-Lc	Respiratory	4,053	27.4	22.1	35.6	31.9
Asthalin	Respiratory	3,183	8.4	99.4	5.9	5.1
Ibugesic Plus	Pain / Analgesics	2,973	4.8	71.2	11.6	17.1
Seroflo	Respiratory	2,959	-1.3	70.3	6.4	5.3
Dytor Plus	Cardiac	2,691	28.3	87.5	35.6	46.2
Urimax-D	Urology	2,498	9.2	45.2	10.3	3.1

Secondary sales grew 18.7% YoY in Jun'26 vs. 14.2% in May'26. Among the top 10 drugs, exceptional growth in Montair- Lc/Dytor Plus/ Dytor/Budecort, except Urimax-D/Seroflo/ Ibugesic Plus/Asthalin/Duolin/Foracort

Exceptional momentum in Anti-Diabetic offset by subdued performance in Gastro/Anti-Infectives/ Respiratory


Overall growth was majorly led by price growth on MAT Jun'26 basis.

Exhibit 11: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	10.6	15.4	18.7
Respiratory	37.3	12.6	14.5	14.9
Anti-Infectives	13.4	5.7	7.9	13.5
Cardiac	11.9	14.5	20.4	27.2
Anti Diabetic	5.8	25.8	42.6	55.6
Pain / Analgesics	5.4	6.5	18.1	26.7
Gastro Intestinal	5.0	3.0	10.1	10.6


Source: IQVIA, MOFSL

Exhibit 12: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 13: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Zydus Lifesciences

Exhibit 14: Top 10 drugs

Secondary sales grew 19.8% YoY in Jun'26 vs. 10.1% in May'26. Exceptional performance in Vivitra/ Bilypsa/Lipaglyn/Nasoclear ; subdued performance in Deriphyllin/Atorva Formonide/Amicin/Monotax /Skinlite.

Drug	Therapy	MAT Jun'26		Market share (%)	Growth (%)	
		Value (INR m)	Growth (%)		Last 3M	Jun'26
Total		76,449	11.7	100.0	14.9	19.8
Lipaglyn	Cardiac	3,713	39.8	60.6	43.8	55.0
Deriphyllin	Respiratory	2,420	13.1	99.5	14.2	16.9
Atorva	Cardiac	2,318	18.0	22.8	14.2	15.7
Vivitra	Antineoplast/Immunomodulator	2,165	70.3	29.5	56.4	96.5
Monotax	Anti-Infectives	1,378	-0.4	8.2	-2.0	-5.0
Formonide	Respiratory	1,314	6.1	7.5	6.4	16.5
Amicin	Anti-Infectives	1,233	-6.0	14.6	-1.2	1.2
Bilypsa	Cardiac	1,133	39.9	18.5	42.4	46.2
Skinlite	Derma	1,100	5.9	33.6	9.3	15.1
Nasoclear	Respiratory	1,026	19.7	45.2	23.0	37.6

Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Exhibit 15: Therapy mix (%)


Strong performance in Antineoplast, while subdued performance in Gastro/AI

Overall growth was majorly driven by contribution from new launches and pricing benefit on MAT basis in Jun'26.

	Share	MAT growth (%)	3M*	Jun'26
Total	100	11.7	14.9	19.8
Cardiac	16.3	20.2	22.4	27.7
Respiratory	14.1	13.9	14.1	20.5
Anti-Infectives	11.5	-1.7	3.6	3.4
Antineoplast/Immunomodulator	10.2	42.7	44.5	62.5
Gastro Intestinal	8.7	1.6	3.1	9.6
Pain / Analgesics	7.4	7.4	10.9	12.1


Source: IQVIA, MOFSL

Exhibit 16: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 17: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Alkem

Secondary sales grew 16.4% YoY in Jun'26 vs. 13.5% in May'26. Strong performance in all major brands was offset by subdued performance in A to Z Ns/Pipzo/Xone.

Strong growth in Paon/VMN/Anti-Diabetics/Neuro/Cns, while Al dragged the overall growth

Price growth and new launches majorly contributed to overall YoY growth on MAT basis in Jun'26.

Exhibit 18: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		1,02,730	10.0	100.0	13.6	16.4
Pan	Gastro Intestinal	8,269	15.0	48.4	21.0	24.6
Clavam	Anti-Infectives	7,141	13.7	14.7	12.9	13.4
Pan-D	Gastro Intestinal	6,391	1.6	33.4	4.8	15.2
Taxim-O	Anti-Infectives	3,465	1.2	20.3	9.2	18.4
A To Z Ns	Vitamins/Minerals/Nutrients	3,304	3.8	9.2	-6.3	-5.6
Uprise-D3	Vitamins/Minerals/Nutrients	3,172	21.4	22.5	27.0	28.9
Pipzo	Anti-Infectives	2,586	7.7	24.0	2.3	0.0
Xone	Anti-Infectives	2,501	-3.5	14.9	-0.1	-5.2
Sumo-L	Pain / Analgesics	2,171	21.5	21.4	24.9	23.9
Gemcal	Pain / Analgesics	2,034	13.1	18.5	30.1	43.8

Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 19: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	10.0	13.6	16.4
Anti-Infectives	31.8	4.4	8.0	8.4
Gastro Intestinal	19.9	8.6	11.9	16.2
Vitamins/Minerals/Nutrients	13.0	19.3	21.7	22.0
Pain / Analgesics	10.9	13.5	20.4	26.2
Anti Diabetic	5.1	17.8	24.0	27.3
Neuro / Cns	3.9	7.6	10.1	21.3


Source: IQVIA, MOFSL

Exhibit 20: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 21: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Lupin

Exhibit 22: Top 10 drugs

Lupin's secondary sales grew 17.5% YoY in Jun'26 vs. 17.4% in May'26. Strong outperformance in Huminsulin/Ivabrad/Signoflam was partly offset by muted growth in Telekast-L/Tonact/Rablet-D.

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		91,751	13.0	100.0	17.4	17.5
Gluconorm-G	Anti Diabetic	4,091	11.8	10.9	15.4	19.4
Huminsulin	Anti Diabetic	2,916	27.3	11.4	33.9	38.4
Budamate	Respiratory	2,868	12.5	16.5	-1.2	2.5
Ivabrad	Cardiac	1,865	14.3	60.8	18.0	25.2
Rablet-D	Gastro Intestinal	1,421	4.8	10.8	0.1	-0.4
Tonact	Cardiac	1,147	4.5	11.3	-2.4	-7.0
Telekast-L	Respiratory	1,107	13.3	6.6	7.2	0.0
Cetil	Anti-Infectives	1,067	17.5	9.0	21.1	20.4
Signoflam	Pain / Analgesics	1,021	10.8	8.9	14.2	22.3
Novastat	Cardiac	992	17.8	5.2	24.2	20.0

Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Strong performance in Anti-Diabetic/Cardiac, partially offset by subdued performance in Gastro.


Overall growth was led by volume growth and price benefit on MAT Jun'26 basis.

Exhibit 23: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	13.0	17.4	17.5
Cardiac	24.6	18.8	20.3	20.2
Anti Diabetic	20.7	13.7	27.9	30.5
Respiratory	15.3	19.1	15.2	14.8
Gastro Intestinal	8.3	6.4	7.8	4.7
Anti-Infectives	6.5	8.8	17.4	14.1
Gynaec.	4.9	10.1	13.4	17.4


Source: IQVIA, MOFSL

Exhibit 24: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 25: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



GSK's secondary sales grew 14.2% YoY in Jun'26 vs. 8.9% in May'26. Among the top 10 drugs, subdued performance of Calpol/ Eltroxin/Ceftum/ Betnovate-C dragged down overall performance in Jun'26.

Weaker trends in Hormones/Pain dragged overall growth for Jun'26.

YoY growth was impacted by volume contraction and muted contribution from new launches, despite price-led growth in MAT Jun'26.

GlaxoSmithKline Pharmaceuticals

Exhibit 26: Top 10 drugs

Drug	Therapy	MAT Jun'26		Growth (%)	
		Value (INR m)	Growth (%)	Market share Last 3M (%)	Jun'26
Total		57,326	8.5	100.0	14.2
Augmentin	Anti-Infectives	9,640	12.5	24.6	25.7
Calpol	Pain / Analgesics	4,548	6.9	28.7	8.1
T-Bact	Derma	4,521	13.0	79.6	17.9
Ceftum	Anti-Infectives	3,009	11.7	31.7	7.6
Betnovate-N	Derma	2,730	5.1	99.9	15.5
Eltroxin	Hormones	2,724	5.3	19.9	3.8
Betnovate-C	Derma	2,680	0.6	99.8	9.0
Neosporin	Derma	2,491	15.3	93.5	19.1
Infanrix Hexa	Vaccines	2,068	14.0	43.5	19.1
Ccm	Vitamins/Minerals/Nutrients	1,762	8.7	13.1	4.4

Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 27: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	8.5	10.8	14.2
Derma	28.7	6.2	12.7	17.2
Anti-Infectives	24.8	9.9	8.8	17.9
Vaccines	13.4	14.3	14.0	11.3
Pain / Analgesics	10.4	6.3	7.0	2.0
Hormones	7.2	6.9	5.7	6.2
Vitamins/Minerals/Nutrients	6.5	7.6	10.1	16.0


Source: IQVIA, MOFSL

Exhibit 28: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 29: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Glenmark Pharma

Secondary sales grew 19.2% YoY in Jun'26 vs. 17.7% in May'26. Among the top 10 drugs, Telma Ct/ Telma – Am posted strong growth, offsetting decline in Alex/ Candid- B.

Exhibit 30: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		58,821	14.6	100.0	18.3	19.2
Telma	Cardiac	6,540	19.9	43.5	20.3	20.9
Telma-H	Cardiac	4,713	12.7	43.3	8.1	10.5
Telma-Am	Cardiac	4,481	13.8	31.1	17.5	24.5
Ascoril-Ls	Respiratory	3,200	15.9	25.9	11.6	11.6
Candid	Derma	2,653	10.1	66.5	24.3	13.1
Candid-B	Derma	1,850	7.2	84.0	12.6	9.2
Milibact	Anti-Infectives	1,564	24.9	12.1	24.5	13.3
Alex	Respiratory	1,416	5.9	5.4	-3.0	-6.6
Ascoril +	Respiratory	1,298	2.6	5.1	6.4	12.6
Telma Ct	Cardiac	1,292	16.4	19.4	21.7	26.3

Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Exceptional growth in Anti-Infectives/Antineoplast led overall YoY growth.


Exhibit 31: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	14.6	18.3	19.2
Cardiac	34.9	17.6	18.8	21.4
Derma	24.3	8.7	13.2	10.3
Respiratory	21.2	14.4	15.0	16.1
Anti-Infectives	9.6	23.8	42.9	51.2
Anti Diabetic	4.0	-4.5	-3.4	-4.2
Antineoplast/Immunomodulator	1.6	62.2	32.1	27.1

Source: IQVIA, MOFSL

Overall performance was driven by both price and volume growth on MAT basis in Jun'26.

Exhibit 32: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 33: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Dr. Reddy's Laboratories

Exhibit 34: Top 10 drugs

Secondary sales grew 17.7% YoY in Jun'26 vs. 13.3% in May'26. Exceptional performance in Ketorol/Hexaxim/Menactra; Majority of the top drugs posted healthy double-digit growth, partly offset by decline in Econorm/Voveran.

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		85,488	13.5	100.0	14.6	17.7
Atarax	Respiratory	2,740	12.7	73.2	20.3	22.4
Ketorol	Pain / Analgesics	2,650	20.7	91.7	28.3	31.5
Econorm	Gastro Intestinal	2,487	7.7	91.2	10.5	8.1
Voveran	Pain / Analgesics	2,373	0.8	86.6	-16.6	-18.8
Omez	Gastro Intestinal	2,288	7.0	81.4	10.7	15.5
Hexaxim	Vaccines	2,263	25.6	47.6	40.6	49.2
Venusia	Derma	1,975	18.1	8.6	26.2	18.5
Menactra	Vaccines	1,899	21.7	80.5	32.3	54.9
Zedex	Respiratory	1,794	13.6	22.6	4.6	30.5
Omez D+	Gastro Intestinal	1,750	15.6	15.6	15.2	12.1

Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Exhibit 35: Therapy mix (%)


Healthy double-digit growth across key therapies

Price gain, followed by new launches and volume growth, drove overall growth on MAT basis in Jun'26.

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	13.5	14.6	17.7
Gastro Intestinal	15.3	11.6	17.0	16.1
Respiratory	13.5	11.4	9.6	19.8
Pain / Analgesics	10.5	16.7	16.0	18.8
Cardiac	9.1	13.1	16.3	15.2
Vaccines	7.9	14.1	17.0	27.1
Derma	7.1	14.2	18.4	19.5


Source: IQVIA, MOFSL

Exhibit 36: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 37: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Torrent Pharma

Secondary sales grew 19.9% YoY in Jun'26 vs. 15.1% in May'26. Exceptional outperformance in majority of the Top-10 brands, partially offset by decline in Rantac/Metrogyl/Nexpro-Rd in Jun'26.

Outperformance in Pain/VMN/Anti-Diabetic in Jun'26.

Growth was majorly driven by price and volume growth on MAT Jun'26.

Exhibit 38: Top 10 drugs

Drug	Therapy	MAT Jun'26		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M Jun'26
Total		1,23,224	11.9	100.0	15.8
Cilacar	Cardiac	5,703	20.3	55.4	21.7
Chymoral	Pain / Analgesics	3,813	17.6	89.1	30.2
Shelcal	Vitamins/Minerals/Nutrients	3,807	13.8	34.4	21.0
Rantac	Gastro Intestinal	3,295	-7.1	35.7	0.1
Cilacar-T	Cardiac	3,080	29.2	37.3	31.7
Nexpro-Rd	Gastro Intestinal	2,829	12.1	25.2	12.7
Nikoran	Cardiac	2,747	22.0	53.3	20.6
Nicardia	Cardiac	2,727	29.0	94.8	27.6
Shelcal Xt	Vitamins/Minerals/Nutrients	2,513	6.3	18.6	14.7
Metrogyl	Anti-Parasitic	2,262	-3.2	78.3	-5.0

Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Exhibit 39: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	11.9	15.8	19.9
Cardiac	33.1	16.4	18.3	23.4
Gastro Intestinal	18.9	7.7	10.4	14.7
Neuro / Cns	11.3	13.5	17.3	19.1
Vitamins/Minerals/Nutrients	7.7	14.8	21.3	23.1
Anti Diabetic	7.2	14.0	29.9	37.1
Pain / Analgesics	6.3	15.2	24.2	25.5

Source: IQVIA, MOFSL

Exhibit 40: Acute vs. Chronic (MAT growth)





Exhibit 41: Growth distribution (%) (MAT Jun'26)





Alembic Pharmaceuticals

Exhibit 42: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		32,828	2.1	100.0	6.1	13.1
Azithral	Anti-Infectives	4,188	-0.8	29.6	-0.5	12.0
Wikoryl	Respiratory	1,249	-0.9	8.4	-6.7	1.3
Gestofit	Gynaec.	1,216	10.1	11.3	12.0	18.0
Althrocine	Anti-Infectives	1,106	-14.4	84.3	-9.1	-4.7
Crina-Ncr	Gynaec.	1,021	12.5	30.2	13.1	23.8
Isofit	Gynaec.	963	19.5	6.6	20.9	29.6
Brozeet-LS	Respiratory	792	10.3	6.4	11.6	23.0
Cetani-T	Cardiac	699	20.0	8.5	18.9	19.7
Tellzy-Am	Cardiac	682	5.8	4.7	10.9	13.2
Richar Cr	Gynaec.	661	3.5	3.7	9.9	12.8

* Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 43: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	2.1	6.1	13.1
Anti-Infectives	19.1	-3.9	-2.8	7.0
Cardiac	16.9	6.3	10.0	14.7
Gynaec.	16.7	10.5	15.4	21.6
Respiratory	12.7	1.8	-0.3	6.3
Gastro Intestinal	9.4	-7.2	0.5	9.8
Anti Diabetic	8.4	1.7	7.5	12.7


Source: IQVIA, MOFSL

Exhibit 44: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 45: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL

Alembic's secondary sales grew 13.1% YoY in Jun'26 vs. 2.7% grew in May'26.

Among the top 10 drugs, decline in Wikoryl/ Athrocine dragged the overall performance despite healthy performance in Isofit/ Crina-Ncr.

Decline in Gastro/AI/ Respiratory dragged overall growth for Jun'26.

Volume decline impacted YoY growth despite price growth for MAT Jun'26.



Ipca Laboratories

Secondary sales grew 14.6% YoY in Jun'26 vs. 11.6% in May'26. Subdued performance in Solvin Cols/ Tfct-Nib/ Zerodol-P dragged overall performance.

Exhibit 46: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		55,229	11.7	100.0	12.4	14.6
Zerodol-Sp	Pain / Analgesics	7,143	14.5	62.6	12.6	13.0
Zerodol-P	Pain / Analgesics	3,196	4.8	51.6	5.2	-1.8
Hcqs	Pain / Analgesics	2,202	6.9	82.8	11.5	21.3
Folitrax	Antineoplast/Immunomodulator	1,877	24.3	85.8	15.9	21.8
Ctd-T	Cardiac	1,449	19.8	21.8	16.0	16.6
Zerodol-Th	Pain / Analgesics	1,436	8.0	60.4	13.2	21.6
Solvin Cold	Respiratory	1,100	14.6	7.7	9.8	7.2
Tfct-Nib	Pain / Analgesics	977	18.0	24.0	8.3	-2.9
Ctd	Cardiac	941	12.0	98.2	8.5	10.2
Saaz	Gastro Intestinal	871	15.4	59.7	11.8	20.9

* Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Exhibit 47: Therapy mix (%)


	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	11.7	12.4	14.6
Pain / Analgesics	38.7	11.4	10.8	11.9
Cardiac	12.9	11.7	14.0	20.2
Anti-Infectives	6.6	2.7	2.7	2.8
Antineoplast/Immunomodulator	6.6	29.7	24.0	28.2
Derma	5.8	15.5	32.3	38.8
Urology	5.1	18.1	22.3	24.7

Source: IQVIA, MOFSL

Subdued performance in overall therapies offset exceptional performance in Derma/ Antineoplast.


Price and volume were the key growth drivers for MAT Jun'26.

Exhibit 48: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 49: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Eris Lifesciences

Exhibit 50: Top 10 drugs

Secondary sales grew 13.8% YoY in Jun'26 vs. 13% in May'26. Subdued performance in Glimisave-M/ Eritel Ln dragged overall performance.

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		34,558	9.6	100.0	12.2	13.8
Renerve Plus	Vitamins/Minerals/Nutrients	1,548	7.2	10.4	10.9	21.8
Glimisave Mv	Anti Diabetic	1,452	2.1	10.5	4.6	12.7
Insugen	Anti Diabetic	1,368	21.6	5.4	20.6	26.4
Basalog	Anti Diabetic	1,167	9.2	9.0	13.9	16.5
Glimisave-M	Anti Diabetic	964	-4.2	2.6	-4.4	4.1
Cyblex Mv	Anti Diabetic	602	21.2	51.4	20.1	15.3
Eritel Ln	Cardiac	541	10.8	6.5	-0.9	7.3
Hertraz	Antineoplast/Immunomodulator	517	70.9	7.1	80.5	76.4
Xsulin	Anti Diabetic	493	68.9	1.9	49.8	41.3
Remylin D	Vitamins/Minerals/Nutrients	447	-1.1	9.9	8.5	24.0

* Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Subdued performance in major therapies, except Antineoplast/VMN.


Exhibit 51: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	9.6	12.2	13.8
Anti Diabetic	33.2	10.5	13.8	16.5
Cardiac	15.7	11.2	11.1	12.1
Derma	13.1	13.6	11.1	13.1
Vitamins/Minerals/Nutrients	12.1	10.3	19.9	26.7
Antineoplast/Immunomodulator	6.6	25.6	31.4	33.9
Gynaec.	4.8	15.1	11.6	8.9

Source: IQVIA, MOFSL


Growth was driven by price hikes and new launches on MAT basis in Jun'26.

Exhibit 52: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 53: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Abbott India

Exhibit 54: Top 10 drugs

Secondary sales grew 16.4% YoY in Jun'26 vs. 10.7% in May'26. Healthy growth in Cremaffin Plus/ Influvac/ Vertin offset by subdued performance in Mixtard/ Rybelsus/ Duphalac

Healthy Performance in Gastro/ VMN except Anti Diabetic.

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		1,66,678	8.9	100.0	12.4	16.4
Thyronorm	Hormones	7,845	13.0	57.3	13.1	12.0
Udiliv	Hepatoprotectives	7,533	9.3	51.9	8.8	14.0
Ryzodeg	Anti Diabetic	7,305	12.2	28.6	13.2	12.3
Mixtard	Anti Diabetic	5,529	-28.7	21.6	-34.3	-31.2
Cremaffin Plus	Gastro Intestinal	4,187	18.1	52.6	27.1	34.8
Duphaston	Gynaec.	4,178	8.1	28.8	9.8	15.0
Rybelsus	Anti Diabetic	4,170	-10.1	69.5	-32.3	-35.2
Duphalac	Gastro Intestinal	4,053	5.1	56.2	10.0	12.1
Influvac	Vaccines	3,990	23.8	69.1	35.0	50.0
Vertin	Neuro / Cns	3,689	17.1	66.0	21.9	36.6

* Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL


Overall growth on MAT basis was mainly driven by price hikes followed by NP launches and volume growth in Jun'26.

Exhibit 55: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	8.9	12.4	16.4
Anti Diabetic	22.2	-3.7	-4.9	-2.0
Gastro Intestinal	16.5	19.1	25.3	30.1
Vitamins/Minerals/Nutrients	9.1	14.0	19.1	26.9
Anti-Infectives	7.7	7.5	13.4	16.4
Cardiac	7.3	15.8	17.0	18.9
Hormones	6.9	13.1	15.7	16.5


Source: IQVIA, MOFSL

Exhibit 56: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 57: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Mankind Pharma

Exhibit 58: Top 10 drugs

Mankind's secondary sales grew 15.1% YoY in Jun'26 vs. 11.1% in May'26. Decline in Unwanted-Kit/Gudcef, subdued growth in Prega News/Moxikind-Cv/ Candiforce/Glimestar-M was offset by healthy growth in Telmikind-Am/ Dydroboon

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		1,25,490	9.0	100.0	12.7	15.1
Manforce	Urology	6,165	10.8	73.4	13.6	17.5
Moxikind-Cv	Anti-Infectives	4,115	3.5	11.4	4.5	6.3
Amlokind-At	Cardiac	3,118	10.5	40.0	15.8	19.5
Unwanted-Kit	Gynaec.	2,544	0.7	55.9	-2.4	-2.5
Dydroboon	Gynaec.	2,530	13.9	17.4	20.1	31.9
Prega News	Others	2,512	8.5	83.5	5.4	3.0
Telmikind-Am	Cardiac	2,230	22.1	15.5	22.5	26.3
Gudcef	Anti-Infectives	2,077	-0.7	17.2	-1.5	-0.6
Candiforce	Derma	2,058	2.3	19.6	7.2	7.9
Glimestar-M	Anti Diabetic	2,045	2.4	5.5	-2.8	2.2

* Three-months: Apr'26-Jun'26

Source: IQVIA, MOFSL

Healthy double-digit growth in VMN/Cardiac; subdued performance in AI


Overall growth was driven by price hikes followed by volume growth & new launches on MAT basis in Jun'26.

Exhibit 59: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	9.0	12.7	15.1
Cardiac	15.9	16.4	19.4	22.8
Anti-Infectives	12.7	1.7	3.6	4.9
Gynaec.	10.5	10.5	12.7	18.6
Gastro Intestinal	9.5	6.7	13.6	12.8
Vitamins/Minerals/Nutrients	8.6	11.4	19.3	22.0
Anti Diabetic	8.6	12.5	12.7	16.6

Source: IQVIA, MOFSL

Exhibit 60: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 61: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Macleods Pharma

Exhibit 62: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		86,796	11.5	100.0	12.3	15.9
Meromac	Anti-Infectives	2,810	6.3	17.5	6.8	9.7
Thyrox	Hormones	2,694	10.3	19.7	2.8	4.7
Omnacortil	Hormones	2,462	17.2	67.8	10.3	13.4
Megalis	Urology	1,800	18.0	60.7	18.8	22.0
Panderm ++	Derma	1,729	1.1	49.8	7.2	10.1
Geminor-M	Anti Diabetic	1,724	15.9	4.6	10.7	15.0
Defcort	Hormones	1,680	11.9	52.7	16.4	21.7
It-Mac	Derma	1,651	9.7	15.9	11.3	11.7
Maczone-Plus	Anti-Infectives	1,638	20.7	12.6	19.8	20.3
Accuzon-Plus	Anti-Infectives	1435	26.0	11.1	20.6	37.0

* Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 63: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	11.5	12.3	15.9
Anti-Infectives	29.6	11.0	11.1	13.5
Cardiac	13.2	13.9	13.1	18.2
Respiratory	9.7	19.4	18.8	26.3
Hormones	8.8	12.2	8.5	11.8
Pain / Analgesics	7.9	9.4	9.7	15.8
Anti-Diabetic	6.3	13.1	14.2	19.5


Source: IQVIA, MOFSL

Exhibit 64: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 65: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL

Secondary sales grew 15.9% YoY in Jun'26 vs. 10.1% in May'26. Strong growth in Accuzon-Plus / Megalis / Defcort offset by subdued performance in Thyrox/ Meromac.

Strong performance registered in Respiratory/ Anti-Diabetic/Cardiac during Jun'26.

Price hikes and volume growth were the key growth for MAT Jun'26 basis



Ajanta Pharma

Exhibit 66: Top 10 drugs

Secondary sales grew 18.3% YoY in Jun'26 vs. 14.7% in May'26. Robust growth in Ivrea/Met XI Trio/Feburic led the overall growth in Jun'26.

Strong double-digit growth across Pain/Anti-Diabetic during Jun'26.

New product launches and price hikes led the overall growth followed by volume growth for MAT Jun'26.

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Jun'26
Total		21609	15.1	100.0	17.8	18.3
Met XI	Cardiac	1805	5.4	24.5	9.4	13.6
Feburic	Pain / Analgesics	1017	9.9	18.7	15.5	25.7
Atorfit-Cv	Cardiac	771	0.3	16.4	9.8	14.5
Melacare	Derma	726	0.2	22.2	7.1	7.7
Met XI Trio	Cardiac	583	19.2	22.8	31.0	26.0
Cinod	Cardiac	569	4.3	5.5	3.6	2.0
Met XI Am	Cardiac	437	9.4	13.5	10.0	13.0
Rosufit-Cv	Cardiac	396	4.6	8.8	13.0	15.9
Ivrea	Derma	386	21.2	61.9	27.7	31.7
Met XI 3D	Cardiac	345	13.5	25.3	16.9	14.3

* Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 67: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	15.1	17.8	18.3
Cardiac	32.4	9.4	14.0	15.7
Ophthal / Otologicals	27.5	15.0	16.3	15.4
Derma	21.0	14.2	13.1	10.9
Pain / Analgesics	8.9	14.6	19.4	25.0
Anti-Diabetic	2.6	21.4	20.9	22.9
Respiratory	1.6	12.4	17.0	13.2


Source: IQVIA, MOFSL

Exhibit 68: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 69: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL



Secondary sales grew 6.8% YoY in Jun'26 vs. 3.9% in May'26. Decline in Metpure-XI/Maxtra partially offset by strong growth in Spegra/Orofer Fcm/Orofer-Xt dragged overall performance in Jun'26.

Subdued performance in Cardiac/AI partially offset by strong performance in Gynaec during Jun'26.

Price hike was the primary growth driver on MAT Jun'26 basis.

Emcure

Exhibit 70: Top 10 drugs

Drug	Therapy	MAT Jun'26			Growth (%)	
		Value (INR m)	Growth (%)	Market Share (%)	Last 3M	Jun'26
Total		57,805	4.6	100.0	5.0	6.8
Orofer-Xt	Gynaec.	2,885	5.7	16.7	9.2	16.1
Zostum	Anti-Infectives	2,689	11.4	29.1	16.4	14.4
Bevon	Vitamins/Minerals/Nutrients	1,727	4.6	22.6	10.1	8.1
Amaryl M	Anti-Diabetic	1,655	-4.9	4.4	2.1	6.5
Orofer Fcm	Gynaec.	1,624	23.3	16.0	23.3	35.4
Maxtra	Respiratory	1,177	-2.2	11.6	-4.1	-7.0
Clexane	Cardiac	1,041	-11.1	11.4	-9.0	17.5
Metpure-XI	Cardiac	939	-6.8	85.8	-13.0	-6.4
Spegra	Antiviral	891	52.6	35.5	36.1	56.3
Amaryl	Anti-Diabetic	873	7.2	27.6	19.8	25.9

* Three-months: Apr'26-Jun'26


Source: IQVIA, MOFSL

Exhibit 71: Therapy mix (%)

	Share	MAT growth (%)	3M*	Jun'26
Total	100.0	4.6	5.0	6.8
Cardiac	18.8	0.7	-1.5	3.1
Gynaec.	18.0	6.8	6.4	13.0
Anti-Infectives	11.6	0.5	4.1	5.9
Anti-Diabetic	7.8	-5.7	3.1	6.8
Antineoplast/Immunomodulator	6.9	39.5	36.6	20.7
Pain/Analgesics	6.4	1.2	-7.3	-9.7


Source: IQVIA, MOFSL

Exhibit 72: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 73: Growth distribution (%) (MAT Jun'26)



Source: IQVIA, MOFSL

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE). Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.